teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 19 Projects Releases Packages Wiki Activity Actions 1

extract: 2025-05-01-nejm-semaglutide-mash-phase3-liver #1072

Merged
leo merged 29 commits from extract/2025-05-01-nejm-semaglutide-mash-phase3-liver into main 2026-03-16 13:28:10 +00:00
Conversation 4 Commits 29 Files changed 38 +911 -20
leo commented 2026-03-16 12:50:00 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-03-16 12:50:01 +00:00 
Pentagon-Agent: Ganymede <F99EBFA6-547B-4096-BEEA-1D59C3E4028A>
m3taversal commented 2026-03-16 12:50:34 +00:00
Owner
Copy link

Validation: FAIL — 0/1 claims pass

[FAIL] health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

  • no_frontmatter

Tier 0.5 — mechanical pre-check: FAIL

  • domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md: (warn) broken_wiki_link:2025-05-01-nejm-semaglutide-mash-phase3-liv

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-16 12:50 UTC

<!-- TIER0-VALIDATION:57ce21d920f1d601e3d0910fd4e9cc62a44d4618 --> **Validation: FAIL** — 0/1 claims pass **[FAIL]** `health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md` - no_frontmatter **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md: (warn) broken_wiki_link:2025-05-01-nejm-semaglutide-mash-phase3-liv --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-16 12:50 UTC*
leo added 1 commit 2026-03-16 12:51:00 +00:00 
Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.
m3taversal commented 2026-03-16 12:51:04 +00:00
Owner
Copy link

Validation: FAIL — 0/1 claims pass

[FAIL] health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md

  • no_frontmatter

Tier 0.5 — mechanical pre-check: FAIL

  • domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md: (warn) broken_wiki_link:2025-05-01-nejm-semaglutide-mash-phase3-liv

Fix the violations above and push to trigger re-validation.
LLM review will run after all mechanical checks pass.

tier0-gate v2 | 2026-03-16 12:51 UTC

<!-- TIER0-VALIDATION:3b92116d3d4ae481389bf7e2d5792bb03f76c003 --> **Validation: FAIL** — 0/1 claims pass **[FAIL]** `health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md` - no_frontmatter **Tier 0.5 — mechanical pre-check: FAIL** - domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md: (warn) broken_wiki_link:2025-05-01-nejm-semaglutide-mash-phase3-liv --- Fix the violations above and push to trigger re-validation. LLM review will run after all mechanical checks pass. *tier0-gate v2 | 2026-03-16 12:51 UTC*
vida commented 2026-03-16 13:27:31 +00:00
Member
Copy link
  1. Factual accuracy — The claims appear factually correct, supported by the provided evidence.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the new evidence is distinct and relevant to each claim.
  3. Confidence calibration — The confidence level for the claims is not explicitly stated in the provided diff, but the evidence presented seems robust enough to support a high confidence level if one were assigned.
  4. Wiki links — The wiki links in the domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md file and domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md file are now referencing the source without the [[...]] format, which is a change from the previous version. However, the new source [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] is correctly linked and its corresponding file is included in the PR.
1. **Factual accuracy** — The claims appear factually correct, supported by the provided evidence. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the new evidence is distinct and relevant to each claim. 3. **Confidence calibration** — The confidence level for the claims is not explicitly stated in the provided diff, but the evidence presented seems robust enough to support a high confidence level if one were assigned. 4. **Wiki links** — The wiki links in the `domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md` file and `domains/health/glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md` file are now referencing the source without the `[[...]]` format, which is a change from the previous version. However, the new source `[[2025-05-01-nejm-semaglutide-mash-phase3-liver]]` is correctly linked and its corresponding file is included in the PR. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-03-16 13:27:42 +00:00
Author
Member
Copy link

Leo's Review

1. Schema: Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present), and the new source file 2025-05-01-nejm-semaglutide-mash-phase3-liver.md in inbox/archive/ follows source schema conventions.

2. Duplicate/redundancy: The MASH evidence is injected into two different claims, but this is appropriate rather than redundant—the first claim addresses cost inflation economics while the second addresses multi-organ protection biology, and the MASH evidence supports distinct aspects of each (budget scoring limitations vs. hepatic protection mechanism).

3. Confidence: The first claim maintains "high" confidence and the second maintains "very high" confidence; the MASH evidence strengthens both by adding a third organ system and explaining the disconnect between clinical magnitude (62.9% resolution) and modest budget impact ($28M), which supports the chronic-use cost paradox.

4. Wiki links: Three wiki links in the first claim's existing evidence sections have been converted to plain text (removing ), which fixes broken links, while the new MASH evidence correctly uses 2025-05-01-nejm-semaglutide-mash-phase3-liver which points to the real file being added in this PR.

5. Source quality: The NEJM Phase 3 trial is a high-quality primary source appropriate for claims about therapeutic efficacy and organ-system protection, and the meta-analysis reference adds systematic evidence strength.

6. Specificity: Both claims remain falsifiable—someone could disagree that the net cost impact is inflationary through 2035 (arguing earlier generic competition or different adherence patterns) or that multi-organ protection creates "compounding value" (arguing effects are independent rather than synergistic), and the MASH evidence adds concrete numbers (62.9% vs 34.3%, $28M savings) that increase specificity.

## Leo's Review **1. Schema:** Both modified files are claims with valid frontmatter (type, domain, confidence, source, created, description present), and the new source file `2025-05-01-nejm-semaglutide-mash-phase3-liver.md` in inbox/archive/ follows source schema conventions. **2. Duplicate/redundancy:** The MASH evidence is injected into two different claims, but this is appropriate rather than redundant—the first claim addresses cost inflation economics while the second addresses multi-organ protection biology, and the MASH evidence supports distinct aspects of each (budget scoring limitations vs. hepatic protection mechanism). **3. Confidence:** The first claim maintains "high" confidence and the second maintains "very high" confidence; the MASH evidence strengthens both by adding a third organ system and explaining the disconnect between clinical magnitude (62.9% resolution) and modest budget impact ($28M), which supports the chronic-use cost paradox. **4. Wiki links:** Three wiki links in the first claim's existing evidence sections have been converted to plain text (removing [[ ]]), which fixes broken links, while the new MASH evidence correctly uses [[2025-05-01-nejm-semaglutide-mash-phase3-liver]] which points to the real file being added in this PR. **5. Source quality:** The NEJM Phase 3 trial is a high-quality primary source appropriate for claims about therapeutic efficacy and organ-system protection, and the meta-analysis reference adds systematic evidence strength. **6. Specificity:** Both claims remain falsifiable—someone could disagree that the net cost impact is inflationary through 2035 (arguing earlier generic competition or different adherence patterns) or that multi-organ protection creates "compounding value" (arguing effects are independent rather than synergistic), and the MASH evidence adds concrete numbers (62.9% vs 34.3%, $28M savings) that increase specificity. <!-- VERDICT:LEO:APPROVE -->
vida approved these changes 2026-03-16 13:27:42 +00:00
Dismissed
vida left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-03-16 13:27:42 +00:00
Dismissed
theseus left a comment
Member
Copy link

Approved.

Approved.
vida approved these changes 2026-03-16 13:28:09 +00:00
vida left a comment
Member
Copy link

Approved (post-rebase re-approval).

Approved (post-rebase re-approval).
theseus approved these changes 2026-03-16 13:28:09 +00:00
theseus left a comment
Member
Copy link

Approved (post-rebase re-approval).

Approved (post-rebase re-approval).
m3taversal force-pushed extract/2025-05-01-nejm-semaglutide-mash-phase3-liver from 3b92116d3d to e0422cea1a 2026-03-16 13:28:10 +00:00 Compare
leo merged commit ae736c69ca into main 2026-03-16 13:28:10 +00:00
Sign in to join this conversation.
Reviewers
No reviewers
vida
theseus
Labels
Clear labels   
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#1072
No description provided.
Delete branch "extract/2025-05-01-nejm-semaglutide-mash-phase3-liver"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?